Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301A. A. Miller, Mark J. Ratain, Jinseub Hwang et al.|Journal of Clinical Oncology|2007Cited by 16
Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105Pranav Gupta, Mark J. Ratain, A. A. Miller et al.|Journal of Clinical Oncology|2006Cited by 3
Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101A. A. Miller, Mark J. Ratain, Martin J. Edelman et al.|Journal of Clinical Oncology|2006Cited by 2